The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended refusing marketing authorization for three investigational therapies for cancer and transplant-related conditions: Tacquell (autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded; Netherlands Cancer Institute), Yartemlea (narsoplimab; Omeros Ireland Limited), and Xervyteg (allogeneic fecal microbiota…
Read More
EMA Turns Down 3 Therapies Across Oncology, Transplantation
